CLL-787: Efficacy and Safety of Ibrutinib Combined With Venetoclax in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis
Department
Internal Medicine
Document Type
Conference Proceeding
Publication Title
Clinical Lymphoma Myeloma and Leukemia
Conference Name
Society of Hematologic Oncology (SOHO) Annual Meeting
Conference Date
2025-09-03 - 2025-09-06
First Page
S532
DOI
10.1016/S2152-2650(25)01870-1
Volume
25
Issue
Supplement 1
Publication Date
9-1-2025
Recommended Citation
Gill, O., Maqsood, M., Khawar, M. M., Sabir, Z., Shuja, H., Ifikhar, S., Naseem, A., Bakhtiar, M., Hassan, A., Rauf, Z., Haider, M. U., Nasir, N., & Hanif, A. (2025). CLL-787: Efficacy and Safety of Ibrutinib Combined With Venetoclax in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia, 25 (Supplement 1), S532. https://doi.org/10.1016/S2152-2650(25)01870-1
COinS